Cogent Biosciences, Inc. (COGT)
Stock Price:
$2.91 USD
0.32 (12.36%)
Updated Oct 23, 2020 3:16 PM EDT - Market open
Key Info
| Market Cap |
124.37M |
| Revenue (ttm) |
23.87M |
| Net Income (ttm) |
-23.11M |
| Shares Out |
42.74M |
| EPS (ttm) |
-0.75 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$2.91 |
| Previous Close |
$2.59 |
| Change ($) |
0.32 |
| Change (%) |
12.36% |
| Day's Open |
2.61 |
| Day's Range |
2.52 - 3.02 |
| Day's Volume |
449,405 |
| 52-Week Range |
0.30 - 3.72 |
More Stats
| Market Cap |
124.37M |
| Enterprise Value |
107.02M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
42.74M |
| Float |
23.31M |
| EPS (basic) |
-0.75 |
| EPS (diluted) |
-0.75 |
| FCF / Share |
-1.11 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
5.21 |
| PB Ratio |
6.46 |
| Revenue |
23.87M |
| Operating Income |
-23.34M |
| Net Income |
-23.11M |
| Free Cash Flow |
-34.66M |
| Net Cash |
17.35M |
| Net Cash / Share |
0.41 |
| Gross Margin |
100.00% |
| Operating Margin |
-97.79% |
| Profit Margin |
-96.80% |
| FCF Margin |
-145.20% |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
-1,499.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.67*
(60.48% upside)
Low
4.00
Current: $2.91
High
6.00
Target: 4.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 22.50 | 9.73 | 8.36 | 6.36 | 2.99 |
| Revenue Growth | 131.14% | 16.44% | 31.55% | 112.83% | - |
| Gross Profit | 22.50 | 9.73 | 8.36 | 6.36 | 2.99 |
| Operating Income | -32.18 | -36.01 | -26.15 | -19.07 | -6.59 |
| Net Income | -31.83 | -34.53 | -25.49 | -18.12 | -6.59 |
| Shares Outstanding | 30.48 | 24.90 | 10.19 | 10.19 | 10.19 |
| Earnings Per Share | -1.04 | -1.39 | -2.51 | -1.78 | -0.65 |
| Operating Cash Flow | -41.51 | -32.49 | -25.84 | -18.64 | 17.72 |
| Capital Expenditures | 0.17 | -0.55 | -0.91 | -3.31 | -1.99 |
| Free Cash Flow | -41.34 | -33.04 | -26.75 | -21.95 | 15.72 |
| Cash & Equivalents | 38.68 | 79.85 | 42.29 | 69.76 | - |
| Total Debt | 6.03 | - | - | - | - |
| Net Cash / Debt | 32.65 | 79.85 | 42.29 | 69.76 | - |
| Assets | 49.42 | 85.93 | 49.12 | 75.55 | - |
| Liabilities | 17.66 | 25.69 | 20.81 | 23.16 | - |
| Book Value | 31.76 | 60.23 | -48.85 | -24.70 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cogent Biosciences, Inc. |
| Country |
United States |
| CEO |
Charles Wilson |
Stock Information
| Ticker Symbol |
COGT |
| Stock Exchange |
NASDAQ |
| Sector |
Health Technology |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: COGT |
| IPO Date |
March 29, 2018 |
Description
Unum Therapeutics, a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a ?bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.